Surgery Combined Ginsenoside Rg3to Ⅲ-Ⅳ Period Immune Function Of Patients With Endometriosis Research

objective To compare immune function of ginsenoside Rg3and gestrinone in patient with stage III-IV postoperative endometriosis. Compare with gestrinone, observe the clinical effect of ginsenoside Rg3treated stage Ⅲ-Ⅳ of postoperatively endometriosis.Methods A cohort of100conservative surgery patients with stage Ⅲ-Ⅳ postoperative endometriosis were assigned into study group (n=50) to receive ginsenoside Rg3therapy (20mg, orally, once daily) for3successive months as a treatment course, and postitive control group (n=50) to be treated with gestrinone (2.5mg, orally, twice weekly) for3successive months as a treatment course, respectively. We followed up every patient for postoperative1month and3months and compared of pain (VAS score) before and after treatment, gynecological examination, pelvic ultrasound, liver function and CA125of the two groups, etc. CD3+T cell, CD3+CD8+T cell,CD3+CD4+T cell,CD4+/CD8+and IL-6were determined before surgery and after treatment.Results1.Study group was noted as having elevated serum CD3+T cell, CD3+CD8+T cell, CD4+/CD8+ratio at months1and3after treatment (all P<0.05).2.The CD3+CD4+T cell of serum was decreased significantly (P<0.05) after treatment than before the surgery in the study group, there was no statistical differences in the control group(P<0.05).3. At month3postoperatively, study group was found to present lower serum IL-6than preoperative level and control group (both P<0.05). 4.After treatment of one month and three month the pain score (VAS score) and CA125eased significantly (P<0.05) than before, and gradually decreased with the increase of treatment time (P<0.05), the comparation of the two groups to was not statistically significant (P>0.05).5. In the two groups, the CA125of serum was decreased significantly (P<0.05) after treatment than before the surgery and decreases with the increase of treatment time (P<0.05), there were no significant difference between the two groups(P>0.05).6.1n the treatment of endometriosis, there was no obviously change of the ALT、AST and GGT of serum in study groups after treatment than before(P>0.05),1month and3month after treatment of in positive control groups, the ALT and AST of serum had rised(P<0.05), the GGT of had rised after3month treatment(P<0.05), there were statistical differences between the two groups(P<0.05).Conclusion1.Ginsenoside Rg3achieved equivalently high efficacy in immune function as compared with gestrinone.2.Ginsenoside Rg3has a better therapeutic effect in patients with endometriosis, fairly with the positive control of gestrinone.3.There was no abnormal liver function in the treatment of endometriosis with ginsenoside Rg3, but some patients with gestrinone treatment suffered liver damage, it indicates that oral administration of ginsenoside Rg3is relatively safe.4.Ginsenoside Rg3was considered as clinically effective adjuvant medication in patients with endometriosis who underwent surgery.